Check Salarius Pharmaceuticals Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$2.9M
EPS (TTM)
0Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0P/B Ratio
0PEG Ratio
0EBITDA
-5.7M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
3044800.00%
Compare market cap, revenue, PE, and other key metrics of Salarius Pharmaceuticals Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
$2.9M | -99.79% | NA | 0.00% | ||
BUY | $60.5B | 241.54% | -505.15 | -12.96% | |
NA | $38.7B | NA | NA | -3.89% | |
BUY | $99.3B | 45.88% | 27.56 | 31.86% | |
BUY | $60.9B | 5.45% | 14.49 | 31.37% |
The Salarius Pharmaceuticals Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Salarius Pharmaceuticals Inc. investment value today
Current value as on today
₹25,857
Returns
Returns from Salarius Pharmaceuticals Inc. Stock
Dollar Returns*
₹4,953 (+4.95%)
Based on 6 analysts
0.00%
Buy
50.00%
Hold
50.00%
Sell
Based on 6 analysts, 50% of analysts recommend a 'SELL' rating for Salarius Pharmaceuticals Inc.. Average target price of $26
Get share price movements and forecasts by analysts on Salarius Pharmaceuticals Inc..
What analysts predicted
78.65%UPSIDE
Target Price
$26
Current Price
$5.55
Analyzed by
6 Analysts
Target
$26.00
Salarius Pharmaceuticals Inc. target price $26, a slight upside of 78.65% compared to current price of $5.55. According to 6 analysts rating.
Search interest for Salarius Pharmaceuticals Inc. Stock has decreased by -67% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 210.8%
Against Peers
In the last 1 year, Beone Medicines Ltd has given 68.4% return, outperforming this stock by 147.5%
Price Dip
In the last 1 month, SLRX stock has moved down by -16.8%
Organisation | Salarius Pharmaceuticals Inc. |
Headquarters | 2450 Holcombe Blvd., Houston, TX, United States, 77021 |
Industry | Health Technology |
CEO | Mr. Mark J. Rosenblum CPA |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Mark J. Rosenblum CPA | Acting CEO, Executive VP of Finance & CFO |
Salarius Pharmaceuticals Inc. share price today is $5.55 as on at the close of the market. Salarius Pharmaceuticals Inc. share today touched a day high of $5.8 and a low of $5.42.
Salarius Pharmaceuticals Inc. share touched a 52 week high of $108 on and a 52 week low of $4.5 on . Salarius Pharmaceuticals Inc. stock price today i.e. is closed at $5.55,which is 94.86% down from its 52 week high and 23.33% up from its 52 week low.
Salarius Pharmaceuticals Inc. market capitalisation is $0.00T as on .
Indian investors can start investing in Salarius Pharmaceuticals Inc. (SLRX) shares with as little as ₹88.114 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.14 in Salarius Pharmaceuticals Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Salarius Pharmaceuticals Inc. share’s latest price of $5.55 as on September 18, 2025 at 1:29 am IST, you will get 1.8018 shares of Salarius Pharmaceuticals Inc.. Learn more about
fractional shares .
Salarius Pharmaceuticals Inc. stock has given -99.79% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?